Adverse events associated with anti-IL-17 agents for psoriasis and psoriatic arthritis: a systematic scoping review

Frontiers in Immunology

Immunology

Yi Ru¹  Jiale Chen¹  Naixuan Lin¹  Jiao Wang²  Miao Zhang²  Liu Liu²  Xin Li²  Chunxiao Wang²  Seokgyeong Hong³  Xiaoying Sun³  Bin Li⁴ 

[1] Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China;Department of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China;Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China;Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China;Institute of Dermatology, Shanghai Academy of Traditional Chinese Medicine, Shanghai, China;Department of Dermatology, Shanghai Skin Disease Hospital, Shanghai, China;

关键词: anti-IL-17;    biological agents;    adverse events;    meta-analysis;    systematic review;   

DOI  :  10.3389/fimmu.2023.993057

 received in 2022-07-13, accepted in 2023-01-10,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundAnti-interleukin (IL)-17 biological agents (BAs) have significant efficacy in the treatment of psoriasis and psoriatic arthritis; however, adverse events (AEs) are common, and their safety has not been systematically evaluated.ObjectivesThe purpose of this systematic review and meta-analysis was to summarize the number and corresponding rates of AEs caused by anti-IL-17 BAs in patients with psoriasis and psoriatic arthritis to improve clinical decision-making regarding their use.MethodsPubMed, Embase, Cochrane Library, and Web of Science databases were independently searched by three authors for articles on the treatment of psoriasis with anti-IL-17 BAs that were published before March 1, 2022, and included at least one AE. Dichotomous variables and 95% confidence intervals (CI) were analyzed using R software (version 4.1.3) and the Meta and Metafor software packages. Funnel plots and meta-regression were used to test for the risk of bias, I2 was used to assess the magnitude of heterogeneity, and subgroup analysis was used to reduce heterogeneity.ResultsA total of 57 studies involving 28,424 patients with psoriasis treated with anti-IL-17 BAs were included in the meta-analysis. Subgroup analysis showed that anti-IL-17A (73.48%) and anti-IL-17A/F (73.12%) BAs were more likely to cause AEs than anti-IL-17R BAs (65.66%). The incidence of AEs was as high as 72.70% with treatment durations longer than one year, and long-term use of medication had the potential to lead to mental disorders. Infection (33.16%), nasopharyngitis (13.74%), and injection site reactions (8.28%) were the most common AEs. Anti-IL-17 BAs were most likely to cause type α (33.52%) AEs. Type δ AEs (1.01%) were rarely observed.ConclusionsAnti-IL-17 BAs used for the treatment of psoriasis and psoriatic arthritis caused a series of AEs, but the symptoms were generally mild.

【 授权许可】

Unknown   
Copyright © 2023 Wang, Wang, Liu, Hong, Ru, Sun, Chen, Zhang, Lin, Li and Li